

Fungal Infection

DIAGNOSIS AND MANAGEMENT

Fourth Edition

MALCOLM D. RICHARDSON
DAVID W. WARNOCK



Contents

Preface to the fourth edition, xxvi

Preface to the first edition, xxviii

Acknowledgements, xxix

1 Introduction, 1

- 1.1 The nature of fungi, 1
- 1.2 Classification and nomenclature of fungi and fungal diseases, 3
- 1.3 Fungi as human pathogens, 5
 - 1.3.1 The superficial mycoses, 5
 - 1.3.2 The subcutaneous mycoses, 6
 - 1.3.3 The systemic mycoses, 6
- 1.4 The changing pattern of fungal infection, 7
- 1.5 New directions in diagnosis, 9
- 1.6 New directions in treatment and prevention, 10
 - Further reading, 11

2 Laboratory diagnosis of fungal infection, 12

- 2.1 Introduction, 12
- 2.2 Collection of specimens, 13
 - 2.2.1 Skin, nails and hair, 14
 - 2.2.2 Mucous membranes, 14
 - 2.2.3 Ear, 15
 - 2.2.4 Eye, 15
 - 2.2.5 Blood, 15
 - 2.2.6 Cerebrospinal fluid, 15
 - 2.2.7 Urine, 16
 - 2.2.8 Other fluids, 16
 - 2.2.9 Lower respiratory tract specimens, 16

- 2.2.10 Pus, 17
- 2.2.11 Bone marrow, 17
- 2.2.12 Tissue, 17
- 2.2.13 Medical devices, 17
- 2.3 Specimens for serological tests, 18
- 2.4 Specimens for antifungal drug level determinations, 18
- 2.5 Transport of specimens, 18
- 2.6 Interpretation of laboratory test results, 18
 - 2.6.1 Direct microscopic examination, 19
 - 2.6.2 Histopathological examination, 19
 - 2.6.3 Immunohistochemistry, 21
 - 2.6.4 In situ hybridization, 21
 - 2.6.5 Culture, 21
 - 2.6.6 Fungal identification, 24
 - 2.6.7 Molecular identification, 25
 - 2.6.8 Serological tests, 26
 - 2.6.9 β -D-glucan detection, 27
- 2.7 Molecular diagnosis of fungal infection, 28
 - Further reading, 30

3 Antifungal drugs, 32

- 3.1 Introduction, 32
- 3.2 Allylamines, 32
 - 3.2.1 Mechanism of action, 32
- 3.3 Terbinafine, 33
 - 3.3.1 Spectrum of activity, 33
 - 3.3.2 Acquired resistance, 33
 - 3.3.3 Pharmacokinetics, 33
 - 3.3.4 Pharmaceuticals, 34
 - 3.3.5 Therapeutic use, 34
 - 3.3.6 Mode of administration, 34
 - 3.3.7 Drug interactions, 34
 - 3.3.8 Toxicity and adverse reactions, 35
- 3.4 Other allylamine compounds for topical administration, 35
 - 3.4.1 Naftifine, 35
- 3.5 Azoles, 35
 - 3.5.1 Mechanism of action, 35
 - 3.5.2 Acquired resistance, 36
 - 3.5.3 Drug interactions, 36
- 3.6 Fluconazole, 40
 - 3.6.1 Spectrum of activity, 40

- 3.6.2 Acquired resistance, 40
- 3.6.3 Pharmacokinetics, 40
- 3.6.4 Pharmaceutics, 41
- 3.6.5 Therapeutic use, 41
- 3.6.6 Mode of administration, 42
- 3.6.7 Drug interactions, 43
- 3.6.8 Toxicity and adverse reactions, 43
- 3.7 Itraconazole, 44
 - 3.7.1 Spectrum of activity, 44
 - 3.7.2 Acquired resistance, 44
 - 3.7.3 Pharmacokinetics, 44
 - 3.7.4 Pharmaceutics, 45
 - 3.7.5 Therapeutic use, 46
 - 3.7.6 Mode of administration, 46
 - 3.7.7 Drug interactions, 47
 - 3.7.8 Toxicity and adverse reactions, 47
- 3.8 Ketoconazole, 48
 - 3.8.1 Spectrum of activity, 48
 - 3.8.2 Acquired resistance, 48
 - 3.8.3 Pharmacokinetics, 48
 - 3.8.4 Pharmaceutics, 48
 - 3.8.5 Therapeutic use, 49
 - 3.8.6 Mode of administration, 49
 - 3.8.7 Drug interactions, 49
 - 3.8.8 Toxicity and adverse reactions, 49
- 3.9 Posaconazole, 50
 - 3.9.1 Spectrum of activity, 50
 - 3.9.2 Acquired resistance, 50
 - 3.9.3 Pharmacokinetics, 50
 - 3.9.4 Pharmaceutics, 51
 - 3.9.5 Therapeutic use, 51
 - 3.9.6 Mode of administration, 52
 - 3.9.7 Drug interactions, 52
 - 3.9.8 Toxicity and adverse reactions, 53
- 3.10 Voriconazole, 53
 - 3.10.1 Spectrum of activity, 53
 - 3.10.2 Acquired resistance, 53
 - 3.10.3 Pharmacokinetics, 53
 - 3.10.4 Pharmaceutics, 54
 - 3.10.5 Therapeutic use, 54
 - 3.10.6 Mode of administration, 55

- 3.10.7 Drug interactions, 56
- 3.10.8 Toxicity and adverse reactions, 56
- 3.11 Other imidazole compounds for topical administration, 57
 - 3.11.1 Bifonazole, 57
 - 3.11.2 Butoconazole, 57
 - 3.11.3 Clotrimazole, 57
 - 3.11.4 Econazole nitrate, 57
 - 3.11.5 Fenticonazole nitrate, 57
 - 3.11.6 Isoconazole nitrate, 57
 - 3.11.7 Miconazole nitrate, 58
 - 3.11.8 Oxiconazole, 58
 - 3.11.9 Sertaconazole nitrate, 58
 - 3.11.10 Sulconazole nitrate, 58
 - 3.11.11 Terconazole, 58
 - 3.11.12 Tioconazole, 58
- 3.12 Echinocandins, 59
 - 3.12.1 Mechanism of action, 59
 - 3.12.2 Spectrum of activity, 59
 - 3.12.3 Acquired resistance, 59
 - 3.12.4 Drug interactions, 60
- 3.13 Anidulafungin, 60
 - 3.13.1 Pharmacokinetics, 60
 - 3.13.2 Pharmaceutics, 60
 - 3.13.3 Therapeutic use, 60
 - 3.13.4 Mode of administration, 61
 - 3.13.5 Drug interactions, 61
 - 3.13.6 Toxicity and adverse reactions, 61
- 3.14 Caspofungin, 61
 - 3.14.1 Pharmacokinetics, 61
 - 3.14.2 Pharmaceutics, 62
 - 3.14.3 Therapeutic use, 62
 - 3.14.4 Mode of administration, 62
 - 3.14.5 Drug interactions, 63
 - 3.14.6 Toxicity and adverse reactions, 63
- 3.15 Micafungin, 63
 - 3.15.1 Pharmacokinetics, 64
 - 3.15.2 Pharmaceutics, 64
 - 3.15.3 Therapeutic use, 64
 - 3.15.4 Mode of administration, 64
 - 3.15.5 Drug interactions, 65
 - 3.15.6 Toxicity and adverse reactions, 65

- 3.16 Polyenes, 65
 - 3.16.1 Mechanism of action, 65
- 3.17 Amphotericin B, 66
 - 3.17.1 Spectrum of activity, 66
 - 3.17.2 Acquired resistance, 66
 - 3.17.3 Pharmacokinetics, 67
 - 3.17.4 Pharmaceutics, 68
 - 3.17.5 Therapeutic use, 69
 - 3.17.6 Mode of administration, 70
 - 3.17.7 Drug interactions, 73
 - 3.17.8 Toxicity and adverse reactions, 73
- 3.18 Other polyene compounds for topical administration, 76
 - 3.18.1 Natamycin, 76
 - 3.18.2 Nystatin, 76
- 3.19 Flucytosine, 76
 - 3.19.1 Mechanism of action, 76
 - 3.19.2 Spectrum of activity, 77
 - 3.19.3 Acquired resistance, 77
 - 3.19.4 Pharmacokinetics, 77
 - 3.19.5 Pharmaceutics, 78
 - 3.19.6 Therapeutic use, 78
 - 3.19.7 Mode of administration, 78
 - 3.19.8 Drug interactions, 78
 - 3.19.9 Toxicity and adverse reactions, 79
- 3.20 Griseofulvin, 79
 - 3.20.1 Mechanism of action, 79
 - 3.20.2 Spectrum of activity, 79
 - 3.20.3 Acquired resistance, 80
 - 3.20.4 Pharmacokinetics, 80
 - 3.20.5 Pharmaceutics, 80
 - 3.20.6 Therapeutic use, 80
 - 3.20.7 Mode of administration, 80
 - 3.20.8 Drug interactions, 81
 - 3.20.9 Toxicity and adverse reactions, 81
- 3.21 Other miscellaneous compounds for topical administration, 81
 - 3.21.1 Amorolfine hydrochloride, 81
 - 3.21.2 Butenafine hydrochloride, 81
 - 3.21.3 Ciclopiroxolamine, 82
 - 3.21.4 Haloprogin, 82
 - 3.21.5 Tolnaftate, 82

- 3.22 Prophylactic treatment for prevention of fungal infection, 82
- 3.23 Empirical treatment of suspected fungal infection in the neutropenic patient, 84
- 3.24 Pre-emptive antifungal treatment, 85
- 3.25 Combination antifungal treatment of invasive fungal infections, 85
- 3.26 Laboratory monitoring, 86
 - 3.26.1 Antifungal drug susceptibility testing, 86
 - 3.26.2 Monitoring of blood concentrations of antifungal drugs, 88
- Further reading, 89

4 Dermatophytosis, 91

- 4.1 Introduction, 91
- 4.2 The causal organisms and their habitat, 92
- 4.3 Epidemiology, 93
- 4.4 Laboratory diagnosis of dermatophytosis, 94
- 4.5 Tinea capitis, 95
 - 4.5.1 Definition, 95
 - 4.5.2 Geographical distribution, 96
 - 4.5.3 Causal organisms, 96
 - 4.5.4 Epidemiology, 96
 - 4.5.5 Clinical manifestations, 97
 - 4.5.6 Differential diagnosis, 99
 - 4.5.7 Essential investigations and their interpretation, 99
 - 4.5.8 Management, 100
 - 4.5.9 Prevention, 101
- 4.6 Tinea corporis, 102
 - 4.6.1 Definition, 102
 - 4.6.2 Geographical distribution, 102
 - 4.6.3 Causal organisms, 102
 - 4.6.4 Epidemiology, 102
 - 4.6.5 Clinical manifestations, 103
 - 4.6.6 Differential diagnosis, 103
 - 4.6.7 Essential investigations and their interpretation, 103
 - 4.6.8 Management, 104
 - 4.6.9 Prevention, 104
- 4.7 Tinea cruris, 105
 - 4.7.1 Definition, 105
 - 4.7.2 Geographical distribution, 105

- 4.7.3 Causal organisms, 105
- 4.7.4 Epidemiology, 105
- 4.7.5 Clinical manifestations, 105
- 4.7.6 Differential diagnosis, 106
- 4.7.7 Essential investigations and their interpretation, 106
- 4.7.8 Management, 106
- 4.7.9 Prevention, 107
- 4.8 Tinea pedis, 107
 - 4.8.1 Definition, 107
 - 4.8.2 Geographical distribution, 107
 - 4.8.3 Causal organisms, 107
 - 4.8.4 Epidemiology, 107
 - 4.8.5 Clinical manifestations, 108
 - 4.8.6 Differential diagnosis, 109
 - 4.8.7 Essential investigations and their interpretation, 109
 - 4.8.8 Management, 109
 - 4.8.9 Prevention, 110
- 4.9 Tinea manuum, 111
 - 4.9.1 Definition, 111
 - 4.9.2 Geographical distribution, 111
 - 4.9.3 Causal organisms, 111
 - 4.9.4 Epidemiology, 111
 - 4.9.5 Clinical manifestations, 111
 - 4.9.6 Differential diagnosis, 112
 - 4.9.7 Essential investigations and their interpretation, 112
 - 4.9.8 Management, 112
 - 4.9.9 Prevention, 113
- 4.10 Tinea unguium, 113
 - 4.10.1 Definition, 113
 - 4.10.2 Geographical distribution, 113
 - 4.10.3 Causal organisms, 113
 - 4.10.4 Epidemiology, 113
 - 4.10.5 Clinical manifestations, 114
 - 4.10.6 Differential diagnosis, 115
 - 4.10.7 Essential investigations and their interpretation, 116
 - 4.10.8 Management, 116
 - 4.10.9 Prevention, 118
 - Further reading, 119
- 5 Superficial candidosis, 121**
 - 5.1 Definition, 121

- 5.2 Geographical distribution, 121
- 5.3 The causal organisms and their habitat, 121
- 5.4 Epidemiology, 122
- 5.5 Clinical manifestations, 124
 - 5.5.1 Oropharyngeal candidosis, 124
 - 5.5.2 Vaginal candidosis, 126
 - 5.5.3 Penile candidosis, 127
 - 5.5.4 Cutaneous candidosis, 127
 - 5.5.5 *Candida* nail infection, 128
 - 5.5.6 Chronic mucocutaneous candidosis, 129
- 5.6 Essential investigations and their interpretation, 130
- 5.7 Management, 130
 - 5.7.1 Oropharyngeal candidosis, 130
 - 5.7.2 Vaginal candidosis, 132
 - 5.7.3 Penile candidosis, 134
 - 5.7.4 Cutaneous candidosis, 134
 - 5.7.5 *Candida* nail infection, 135
 - 5.7.6 Chronic mucocutaneous candidosis, 135
- 5.8 Prevention, 136
 - Further reading, 137
- 6 Other cutaneous fungal infections, 138**
 - 6.1 Pityriasis versicolor, 138
 - 6.1.1 Definition, 138
 - 6.1.2 Geographical distribution, 138
 - 6.1.3 The causal organisms and their habitat, 138
 - 6.1.4 Epidemiology, 139
 - 6.1.5 Clinical manifestations, 140
 - 6.1.6 Differential diagnosis, 140
 - 6.1.7 Essential investigations and their interpretation, 141
 - 6.1.8 Management, 141
 - 6.2 Other *Malassezia* infections, 142
 - 6.2.1 *Malassezia* folliculitis, 142
 - 6.2.2 Seborrhoeic dermatitis, 142
 - 6.3 Piedra, 143
 - 6.4 White piedra, 144
 - 6.4.1 Definition, 144
 - 6.4.2 Geographical distribution, 144
 - 6.4.3 The causal organisms and their habitat, 144
 - 6.4.4 Epidemiology, 144
 - 6.4.5 Clinical manifestations, 144

- 6.4.6 Differential diagnosis, 145
- 6.4.7 Essential investigations and their interpretation, 145
- 6.4.8 Management, 145
- 6.5 Black piedra, 145
 - 6.5.1 Definition, 145
 - 6.5.2 Geographical distribution, 146
 - 6.5.3 The causal organism and its habitat, 146
 - 6.5.4 Epidemiology, 146
 - 6.5.5 Clinical manifestations, 146
 - 6.5.6 Differential diagnosis, 146
 - 6.5.7 Essential investigations and their interpretation, 146
 - 6.5.8 Management, 147
- 6.6 Tinea nigra, 147
 - 6.6.1 Definition, 147
 - 6.6.2 Geographical distribution, 147
 - 6.6.3 The causal organism and its habitat, 147
 - 6.6.4 Epidemiology, 147
 - 6.6.5 Clinical manifestations, 147
 - 6.6.6 Differential diagnosis, 148
 - 6.6.7 Essential investigations and their interpretation, 148
 - 6.6.8 Management, 148
- 6.7 *Neoscytalidium* infection, 148
- 6.8 *Alternaria* infection, 149
 - Further reading, 150
- 7** Mould infections of nails, 151
 - 7.1 Definition, 151
 - 7.2 Geographical distribution, 151
 - 7.3 The causal organisms and their habitat, 151
 - 7.4 Epidemiology, 152
 - 7.5 Clinical manifestations, 152
 - 7.6 Differential diagnosis, 153
 - 7.7 Essential investigations and their interpretation, 153
 - 7.8 Management, 154
 - 7.9 Prevention, 155
 - Further reading, 155
- 8** Keratomycosis, 156
 - 8.1 Definition, 156
 - 8.2 Geographical distribution, 156

- 8.3 The causal organisms and their habitat, 156
- 8.4 Epidemiology, 157
- 8.5 Clinical manifestations, 158
- 8.6 Essential investigations and their interpretation, 159
- 8.7 Management, 160
 - Further reading, 161
- 9 Otomycosis, 162**
 - 9.1 Definition, 162
 - 9.2 Geographical distribution, 162
 - 9.3 The causal organisms and their habitat, 162
 - 9.4 Epidemiology, 162
 - 9.5 Clinical manifestations, 163
 - 9.6 Differential diagnosis, 164
 - 9.7 Essential investigations and their interpretation, 164
 - 9.8 Management, 164
 - Further reading, 165
- 10 Aspergillosis, 166**
 - 10.1 Definition, 166
 - 10.2 Geographical distribution, 166
 - 10.3 The causal organisms and their habitat, 166
 - 10.4 Epidemiology, 167
 - 10.5 Clinical manifestations, 170
 - 10.5.1 Acute invasive pulmonary aspergillosis, 171
 - 10.5.2 Tracheobronchitis and obstructing bronchial aspergillosis, 172
 - 10.5.3 Acute invasive *Aspergillus* rhinosinusitis, 173
 - 10.5.4 CNS aspergillosis, 174
 - 10.5.5 Cutaneous aspergillosis, 175
 - 10.5.6 Simple pulmonary aspergilloma, 176
 - 10.5.7 Chronic pulmonary aspergillosis, 176
 - 10.5.8 Chronic invasive *Aspergillus* rhinosinusitis, 177
 - 10.5.9 Chronic granulomatous *Aspergillus* sinusitis, 178
 - 10.5.10 Paranasal sinus fungal ball, 178
 - 10.5.11 Endocarditis, myocarditis and pericarditis, 179
 - 10.5.12 Osteomyelitis and arthritis, 179
 - 10.5.13 Endophthalmitis, 180
 - 10.5.14 Allergic bronchopulmonary aspergillosis, 180
 - 10.5.15 Allergic rhinosinusitis, 181
 - 10.6 Essential investigations and their interpretation, 182
 - 10.6.1 Microscopy, 182

- 10.6.2 Culture, 183
- 10.6.3 Skin tests, 183
- 10.6.4 Serological tests, 183
- 10.6.5 Antigen detection tests, 184
- 10.6.6 β -D-glucan detection, 186
- 10.6.7 Molecular diagnostics, 186
- 10.7 Management, 186
 - 10.7.1 Acute invasive pulmonary aspergillosis, 186
 - 10.7.2 Tracheobronchitis and obstructing bronchial aspergillosis, 190
 - 10.7.3 Acute invasive *Aspergillus* rhinosinusitis, 190
 - 10.7.4 CNS aspergillosis, 191
 - 10.7.5 Cutaneous aspergillosis, 191
 - 10.7.6 Simple pulmonary aspergilloma, 191
 - 10.7.7 Chronic pulmonary aspergillosis, 192
 - 10.7.8 Chronic invasive *Aspergillus* rhinosinusitis, 192
 - 10.7.9 Chronic granulomatous *Aspergillus* rhinosinusitis, 192
 - 10.7.10 Paranasal sinus fungal ball, 192
 - 10.7.11 Endocarditis, myocarditis and pericarditis, 192
 - 10.7.12 Osteomyelitis and arthritis, 193
 - 10.7.13 Endophthalmitis, 193
 - 10.7.14 Allergic bronchopulmonary aspergillosis, 194
 - 10.7.15 Allergic rhinosinusitis, 194
- 10.8 Empirical treatment of suspected invasive aspergillosis, 194
- 10.9 Prevention, 195
 - 10.9.1 Environmental strategies, 195
 - 10.9.2 Therapeutic strategies, 197
- Further reading, 198
- 11 Invasive candidosis, 201**
 - 11.1 Definition, 201
 - 11.2 Geographical distribution, 201
 - 11.3 The causal organisms and their habitat, 201
 - 11.4 Epidemiology, 202
 - 11.5 Clinical manifestations, 208
 - 11.5.1 Acute disseminated candidosis and candidaemia, 208
 - 11.5.2 Chronic disseminated candidosis, 209
 - 11.5.3 Lower urinary tract candidosis, 210
 - 11.5.4 Renal candidosis, 210

- 11.5.5 Respiratory tract candidosis, 211
- 11.5.6 Osteomyelitis and arthritis, 212
- 11.5.7 Peritonitis, 212
- 11.5.8 Endocarditis, myocarditis, pericarditis and other vascular infections, 213
- 11.5.9 Central nervous system candidosis, 214
- 11.5.10 Endophthalmitis and chorioretinitis, 215
- 11.5.11 Oesophagitis, 215
- 11.5.12 Gastrointestinal candidosis, 216
- 11.5.13 Intrauterine candidosis, 216
- 11.6 Candidosis in special hosts, 217
 - 11.6.1 Drug abusers, 217
- 11.7 Essential investigations and their interpretation, 217
 - 11.7.1 Microscopy, 217
 - 11.7.2 Culture, 217
 - 11.7.3 Serological tests, 219
 - 11.7.4 Antigen detection tests, 219
 - 11.7.5 β -D-glucan detection, 220
 - 11.7.6 D-arabinitol detection, 220
 - 11.7.7 Molecular diagnostics, 221
- 11.8 Management, 221
 - 11.8.1 Acute disseminated candidosis and candidaemia, 221
 - 11.8.2 Chronic disseminated candidosis, 225
 - 11.8.3 Lower urinary tract candidosis, 226
 - 11.8.4 Renal candidosis, 227
 - 11.8.5 Respiratory tract candidosis, 227
 - 11.8.6 Osteomyelitis and arthritis, 227
 - 11.8.7 Peritonitis, 228
 - 11.8.8 Endocarditis, myocarditis, pericarditis and other vascular infections, 229
 - 11.8.9 CNS candidosis, 230
 - 11.8.10 Endophthalmitis and chorioretinitis, 230
 - 11.8.11 Oesophagitis, 231
- 11.9 Empirical treatment of suspected invasive candidosis, 232
- 11.10 Prevention, 232
 - Further reading, 234

12 Cryptococcosis, 236

- 12.1 Definition, 236

- 12.2 Geographical distribution, 236
- 12.3 The causal organisms and their habitat, 236
- 12.4 Epidemiology, 238
- 12.5 Clinical manifestations, 240
 - 12.5.1 Pulmonary cryptococcosis, 241
 - 12.5.2 CNS cryptococcosis, 241
 - 12.5.3 Cutaneous cryptococcosis, 243
 - 12.5.4 Osteomyelitis, 244
 - 12.5.5 Other forms of cryptococcosis, 244
- 12.6 Essential investigations and their interpretation, 244
 - 12.6.1 Microscopy, 244
 - 12.6.2 Culture, 245
 - 12.6.3 Serological tests, 245
 - 12.6.4 Antigen detection tests, 245
- 12.7 Management, 246
 - 12.7.1 CNS cryptococcosis, 247
 - 12.7.2 Pulmonary cryptococcosis, 248
 - 12.7.3 Cryptococcoma, 249
 - 12.7.4 Other forms of cryptococcosis, 249
 - 12.7.5 Management of persistent and relapsing cryptococcosis, 250
 - 12.7.6 Management of increased intracranial pressure, 250
 - 12.7.7 Management of IRIS, 250
- 12.8 Prevention, 251
 - Further reading, 251
- 13 Mucormycosis, 253**
 - 13.1 Definition, 253
 - 13.2 Geographical distribution, 253
 - 13.3 The causal organisms and their habitat, 253
 - 13.4 Epidemiology, 254
 - 13.5 Clinical manifestations, 256
 - 13.5.1 Rhinocerebral mucormycosis, 256
 - 13.5.2 Pulmonary mucormycosis, 257
 - 13.5.3 Cutaneous mucormycosis, 258
 - 13.5.4 Gastrointestinal mucormycosis, 258
 - 13.5.5 Disseminated mucormycosis, 259
 - 13.5.6 Other forms of mucormycosis, 259
 - 13.6 Differential diagnosis, 259
 - 13.7 Essential investigations and their interpretation, 259
 - 13.7.1 Microscopy, 259

- 13.7.2 Culture, 260
- 13.7.3 Serological and molecular tests, 260
- 13.8 Management, 260
- 13.9 Prevention, 262
 - Further reading, 263
- 14 Pneumocystosis, 264**
 - 14.1 Definition, 264
 - 14.2 Geographical distribution, 264
 - 14.3 The causal organisms and their habitat, 264
 - 14.4 Epidemiology, 265
 - 14.5 Clinical manifestations, 268
 - 14.6 Differential diagnosis, 269
 - 14.7 Essential investigations and their interpretation, 270
 - 14.7.1 Microscopy, 270
 - 14.7.2 Serological tests, 270
 - 14.7.3 β -D-glucan detection, 271
 - 14.7.4 Molecular diagnostics, 271
 - 14.8 Management, 271
 - 14.9 Prevention, 274
 - Further reading, 276
- 15 Blastomycosis, 277**
 - 15.1 Definition, 277
 - 15.2 Geographical distribution, 277
 - 15.3 The causal organism and its habitat, 277
 - 15.4 Epidemiology, 278
 - 15.5 Clinical manifestations, 279
 - 15.5.1 Pulmonary blastomycosis, 279
 - 15.5.2 Cutaneous blastomycosis, 280
 - 15.5.3 Osteoarticular blastomycosis, 280
 - 15.5.4 Genitourinary blastomycosis, 281
 - 15.5.5 Other forms of disseminated blastomycosis, 281
 - 15.6 Differential diagnosis, 282
 - 15.7 Essential investigations and their interpretation, 282
 - 15.7.1 Microscopy, 282
 - 15.7.2 Culture, 282
 - 15.7.3 Serological tests, 283
 - 15.7.4 Antigen detection tests, 283
 - 15.8 Management, 283
 - 15.8.1 Pulmonary blastomycosis, 283

- 15.8.2 Disseminated blastomycosis, 284
- 15.8.3 Immunocompromised patients with blastomycosis, 285
- 15.9 Prevention, 286
 - Further reading, 286
- 16 Coccidioidomycosis, 288**
 - 16.1 Definition, 288
 - 16.2 Geographical distribution, 288
 - 16.3 The causal organisms and their habitat, 288
 - 16.4 Epidemiology, 289
 - 16.5 Clinical manifestations, 291
 - 16.5.1 Acute pulmonary coccidioidomycosis, 291
 - 16.5.2 Chronic pulmonary coccidioidomycosis, 292
 - 16.5.3 Disseminated coccidioidomycosis, 292
 - 16.6 Differential diagnosis, 294
 - 16.7 Essential investigations and their interpretation, 294
 - 16.7.1 Microscopy, 294
 - 16.7.2 Culture, 294
 - 16.7.3 Skin tests, 295
 - 16.7.4 Serological tests, 295
 - 16.7.5 Antigen detection tests, 297
 - 16.8 Management, 297
 - 16.8.1 Acute pulmonary coccidioidomycosis, 297
 - 16.8.2 Chronic pulmonary coccidioidomycosis, 299
 - 16.8.3 Disseminated coccidioidomycosis, 299
 - 16.8.4 Meningitis, 300
 - 16.9 Prevention, 301
 - Further reading, 302
- 17 Histoplasmosis, 304**
 - 17.1 Definition, 304
 - 17.2 Geographical distribution, 304
 - 17.3 The causal organism and its habitat, 305
 - 17.4 Epidemiology, 305
 - 17.5 Clinical manifestations, 307
 - 17.5.1 Acute pulmonary histoplasmosis, 308
 - 17.5.2 Chronic pulmonary histoplasmosis, 309
 - 17.5.3 Disseminated histoplasmosis, 310
 - 17.5.4 African histoplasmosis, 312
 - 17.6 Differential diagnosis, 312

- 17.7 Essential investigations and their interpretation, 313
 - 17.7.1 Microscopy, 313
 - 17.7.2 Culture, 313
 - 17.7.3 Skin tests, 314
 - 17.7.4 Serological tests, 314
 - 17.7.5 Antigen detection tests, 315
- 17.8 Management, 316
 - 17.8.1 Acute pulmonary histoplasmosis, 316
 - 17.8.2 Chronic pulmonary histoplasmosis, 318
 - 17.8.3 Disseminated histoplasmosis, 318
 - 17.8.4 CNS histoplasmosis, 319
- 17.9 Prevention, 320
 - Further reading, 321

18 Paracoccidioidomycosis, 322

- 18.1 Definition, 322
- 18.2 Geographical distribution, 322
- 18.3 The causal organism and its habitat, 322
- 18.4 Epidemiology, 323
- 18.5 Clinical manifestations, 324
 - 18.5.1 Pulmonary paracoccidioidomycosis, 325
 - 18.5.2 Mucocutaneous paracoccidioidomycosis, 325
 - 18.5.3 Other forms of disseminated paracoccidioidomycosis, 326
- 18.6 Differential diagnosis, 327
- 18.7 Essential investigations and their interpretation, 327
 - 18.7.1 Microscopy, 327
 - 18.7.2 Culture, 327
 - 18.7.3 Serological tests, 328
 - 18.7.4 Antigen detection tests, 329
- 18.8 Management, 329
- 18.9 Prevention, 331
 - Further reading, 331

19 Chromoblastomycosis, 332

- 19.1 Definition, 332
- 19.2 Geographical distribution, 332
- 19.3 The causal organisms and their habitat, 332
- 19.4 Epidemiology, 333
- 19.5 Clinical manifestations, 333
- 19.6 Differential diagnosis, 334

19.7 Essential investigations and their interpretation, 334

19.7.1 Microscopy, 335

19.7.2 Culture, 335

19.8 Management, 335

Further reading, 336

20 Entomophthoromycosis, 338

20.1 Introduction, 338

20.2 Basidiobolomycosis, 338

20.2.1 Definition, 338

20.2.2 Geographical distribution, 339

20.2.3 The causal organism and its habitat, 339

20.2.4 Epidemiology, 339

20.2.5 Clinical manifestations, 339

20.2.6 Essential investigations and their interpretation, 340

20.2.7 Management, 340

20.3 Conidiobolomycosis, 341

20.3.1 Definition, 341

20.3.2 Geographical distribution, 341

20.3.3 The causal organisms and their habitat, 341

20.3.4 Epidemiology, 341

20.3.5 Clinical manifestations, 341

20.3.6 Essential investigations and their interpretation, 342

20.3.7 Management, 342

Further reading, 343

21 Mycetoma, 344

21.1 Definition, 344

21.2 Geographical distribution, 344

21.3 The causal organisms and their habitat, 344

21.4 Epidemiology, 346

21.5 Clinical manifestations, 346

21.6 Differential diagnosis, 347

21.7 Essential investigations and their interpretation, 348

21.7.1 Gross examination, 348

21.7.2 Microscopy, 348

21.7.3 Culture, 348

21.7.4 Serological tests, 349

- 21.8 Management, 349
 - Further reading, 351

22 Sporotrichosis, 352

- 22.1 Definition, 352
- 22.2 Geographical distribution, 352
- 22.3 The causal organism and its habitat, 352
- 22.4 Epidemiology, 353
- 22.5 Clinical manifestations, 354
 - 22.5.1 Lymphocutaneous sporotrichosis, 354
 - 22.5.2 Extracutaneous sporotrichosis, 355
- 22.6 Differential diagnosis, 356
- 22.7 Essential investigations and their interpretation, 357
 - 22.7.1 Microscopy, 357
 - 22.7.2 Culture, 357
 - 22.7.3 Serological tests, 357
- 22.8 Management, 358
 - 22.8.1 Lymphocutaneous sporotrichosis, 358
 - 22.8.2 Extracutaneous sporotrichosis, 359
- 22.9 Prevention, 360
 - Further reading, 360

23 Hyalohyphomycosis, 362

- 23.1 Introduction, 362
- 23.2 *Fusarium* infection, 362
 - 23.2.1 Geographical distribution, 363
 - 23.2.2 The causal organisms and their habitat, 363
 - 23.2.3 Epidemiology, 363
 - 23.2.4 Clinical manifestations, 365
 - 23.2.5 Essential investigations and their interpretation, 366
 - 23.2.6 Management, 367
 - 23.2.7 Prevention, 368
- 23.3 *Scedosporium* infection, 369
 - 23.3.1 Geographical distribution, 369
 - 23.3.2 The causal organisms and their habitat, 369
 - 23.3.3 Epidemiology, 370
 - 23.3.4 Clinical manifestations, 371
 - 23.3.5 Essential investigations and their interpretation, 372
 - 23.3.6 Management, 372
- 23.4 Other agents of hyalohyphomycosis, 373
 - 23.4.1 *Acremonium* infection, 373

- 23.4.2 *Paecilomyces* infection, 373
- 23.4.3 *Scopulariopsis* infection, 374
- Further reading, 374

24 *Penicillium marneffei* infection, 376

- 24.1 Introduction, 376
- 24.2 Geographical distribution, 376
- 24.3 The causal organism and its habitat, 376
- 24.4 Epidemiology, 377
- 24.5 Clinical manifestations, 378
- 24.6 Differential diagnosis, 378
- 24.7 Essential investigations and their interpretation, 379
 - 24.7.1 Microscopy, 379
 - 24.7.2 Culture, 379
 - 24.7.3 Serological tests, 380
- 24.8 Management, 380
- 24.9 Prevention, 381
 - Further reading, 381

25 Phaeohyphomycosis, 383

- 25.1 Introduction, 383
- 25.2 Geographical distribution, 384
- 25.3 The causal organisms and their habitat, 384
- 25.4 Epidemiology, 385
- 25.5 Clinical manifestations, 387
 - 25.5.1 Subcutaneous phaeohyphomycosis, 387
 - 25.5.2 Rhinosinusitis, 388
 - 25.5.3 Pulmonary phaeohyphomycosis, 389
 - 25.5.4 CNS phaeohyphomycosis, 389
 - 25.5.5 Disseminated phaeohyphomycosis, 390
 - 25.5.6 Other forms of phaeohyphomycosis, 390
- 25.6 Differential diagnosis, 390
- 25.7 Essential investigations and their interpretation, 391
 - 25.7.1 Microscopy, 391
 - 25.7.2 Culture, 391
- 25.8 Management, 392
 - 25.8.1 Subcutaneous phaeohyphomycosis, 392
 - 25.8.2 Rhinosinusitis, 393
 - 25.8.3 Pulmonary phaeohyphomycosis, 393
 - 25.8.4 CNS phaeohyphomycosis, 394
 - 25.8.5 Disseminated phaeohyphomycosis, 394

- 25.8.6 Other forms of phaeohyphomycosis, 394
- Further reading, 395

26 Other invasive yeast infections, 396

- 26.1 Introduction, 396
- 26.2 Systemic *Malassezia* infection, 396
 - 26.2.1 Geographical distribution, 396
 - 26.2.2 The causal organisms and their habitat, 397
 - 26.2.3 Epidemiology, 397
 - 26.2.4 Clinical manifestations, 398
 - 26.2.5 Essential investigations and their interpretation, 398
 - 26.2.6 Management, 399
- 26.3 Trichosporonosis, 399
 - 26.3.1 Geographical distribution, 399
 - 26.3.2 The causal organisms and their habitat, 400
 - 26.3.3 Epidemiology, 400
 - 26.3.4 Clinical manifestations, 400
 - 26.3.5 Essential investigations and their interpretation, 401
 - 26.3.6 Management, 402
- 26.4 Other yeast infections, 402
 - 26.4.1 *Blastoschizomyces* infection, 402
 - 26.4.2 *Rhodotorula* infection, 403
 - 26.4.3 *Saccharomyces* infection, 403
 - Further reading, 404

27 Unusual fungal and pseudofungal infections, 405

- 27.1 Introduction, 405
- 27.2 Adiaspiromycosis, 405
 - 27.2.1 Definition, 405
 - 27.2.2 Geographical distribution, 406
 - 27.2.3 The causal organisms and their habitat, 406
 - 27.2.4 Epidemiology, 406
 - 27.2.5 Clinical manifestations, 406
 - 27.2.6 Differential diagnosis, 407
 - 27.2.7 Essential investigations and their interpretation, 407
 - 27.2.8 Management, 408
- 27.3 Lacaziosis, 408
 - 27.3.1 Definition, 408
 - 27.3.2 Geographical distribution, 408

- 27.3.3 The causal organism and its habitat, 408
- 27.3.4 Epidemiology, 409
- 27.3.5 Clinical manifestations, 409
- 27.3.6 Differential diagnosis, 409
- 27.3.7 Essential investigations and their interpretation, 409
- 27.3.8 Management, 410
- 27.4 Pythiosis, 410
 - 27.4.1 Definition, 410
 - 27.4.2 Geographical distribution, 410
 - 27.4.3 The causal organism and its habitat, 411
 - 27.4.4 Epidemiology, 411
 - 27.4.5 Clinical manifestations, 411
 - 27.4.6 Differential diagnosis, 412
 - 27.4.7 Essential investigations and their interpretation, 412
 - 27.4.8 Management, 413
- 27.5 Rhinosporidiosis, 414
 - 27.5.1 Definition, 414
 - 27.5.2 Geographical distribution, 414
 - 27.5.3 The causal organism and its habitat, 414
 - 27.5.4 Epidemiology, 414
 - 27.5.5 Clinical manifestations, 415
 - 27.5.6 Differential diagnosis, 415
 - 27.5.7 Essential investigations and their interpretation, 416
 - 27.5.8 Management, 416
- Further reading, 416

Select bibliography, 419

Index, 421